Martin Lake, Principal NGS Biostatistician
Early‑phase infectious disease research has always had a blind spot. Challenge studies can tell you what happens — viral kinetics, symptom onset, treatment response — but they often struggle to explain why. The biology beneath the clinical readout has historically been inferred, modelled, or left unexplored until much later in development.
Next‑generation sequencing (NGS) changes that equation. It gives developers a molecular‑level view of infection, evolution, and host response at the exact moment those processes unfold. Yet despite its potential, NGS is still underused in early‑phase trials. Not because sponsors don’t want the insight, but because the practical barriers have been high: slow turnaround times, limited sample volumes, fragmented workflows, and analysis pipelines that aren’t built for infectious disease.
The result is a familiar frustration. Sponsors know sequencing could strengthen their programmes, but the path to getting meaningful data has been too slow, too siloed, or too disconnected from the clinical environment to be useful.
That’s the gap this new generation of NGS capability is finally closing.
The industry pain points are clear
Sequencing has been too slow for early‑phase decision‑making. Traditional sequencing workflows rely on external vendors, long queues, and multi‑week turnaround times. By the time data arrives, the window for early interpretation has often passed.
Real‑world samples don’t behave like ideal lab inputs. Challenge studies produce variable viral loads, small volumes, and time‑sensitive samples. Many sequencing labs struggle to extract reliable data from this material.
Data generation is easy — interpretation is not. Most vendors can produce a genome. Very few can tell you which mutations matter, which are noise, and which could influence resistance, efficacy, or regulatory review.
Reference databases are outdated. For fast‑evolving pathogens like influenza, comparing new sequences to old reference genomes produces hundreds of irrelevant differences. Sponsors get data, but not insight.
Sequencing is often disconnected from the clinical context. When NGS sits outside the trial environment, it becomes an isolated dataset rather than a tool that informs dose selection, mechanism, or antiviral performance.
These pain points aren’t theoretical — they’re the reason sequencing has struggled to find its place in early‑phase infectious disease development.
NGS becomes powerful when it’s embedded, not outsourced
The turning point comes when sequencing is integrated directly into the early‑phase environment — when sample handling, laboratory processing, computational biology, and infectious disease expertise operate as a single system.
That’s where the real value emerges:
This is the shift the field has been waiting for.
A flu example: when the reference is wrong, the conclusions are too
One of the clearest illustrations comes from influenza. Many sequencing vendors still compare new flu genomes against reference databases built from strains circulating decades ago. The result is predictable: hundreds of differences, most of them irrelevant.
When developers try to interpret this, they’re left with noise instead of clarity.
By contrast, using a curated, season‑specific database of representative flu strains transforms the analysis. Suddenly, the question isn’t “what changed?” but “what changed that matters?” — especially when assessing antiviral resistance or vaccine performance.
This is the difference between sequencing as a commodity and sequencing as insight.
The next frontier: multi‑pathogen assays and host response
Once sequencing is embedded in the early‑phase environment, its applications expand quickly:
These aren’t speculative ideas — they’re the natural evolution of a platform that can already move from sample to sequence within a working week.
The Bottom Line
NGS has always had the potential to transform early‑phase infectious disease research. What held it back wasn’t the technology — it was the lack of an environment where sequencing, clinical science, and infectious disease expertise could operate together.
That environment now exists. And as sequencing becomes a force multiplier for early‑phase development, sponsors gain something they’ve never truly had before: a molecular‑level understanding of infection and treatment response at the exact moment those insights matter most.
This is the beginning of a new chapter for early‑phase infectious disease research — one where sequencing isn’t an afterthought, but a core part of how smarter, faster decisions get made.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
